OP0027 EFFECT OF SHORT-TERM METHOTREXATE DISCONTINUATION ON THE DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: POSTHOC-ANALYSIS OF TWO RANDOMIZED CLINICAL TRIALS
Authors: Min Jung Kim, Yeong Wook Song, Eun Bong Lee, Jin Kyun Park
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) require a continuous, potentially life-long immune suppression with disease modifying antirheumatic drugs (DMARDs) including methotrexate (MTX). However, in special circumstances such as life-threatening infections, vaccinations or major surgeries, use of MTX should be minimized to restore the treatment-associated immune suppression. While a long-term or permanent discontinuation of MTX is associated with a disease flare or relapse, the effect of short-term discontinuation on disease activity has not been fully elucidated. <h3>Objectives</h3> To investigate the effect of short-term discontinuation of MTX on the disease activity in patients with RA on stable dose of MTX. <h3>Methods</h3> This is a posthoc analysis of 2 randomized controlled studies investigating effect of MTX discontinuation for 2 weeks or 4 weeks on vaccine response to seasonal influenza vaccination in patients with RA. In the 4-week discontinuation study, 54 patients continued MTX and 44 patients discontinued it for 4 weeks before vaccination with trivalent seasonal influenza vaccine. In the 2-week discontinuation study, 159 patients continued MTX and 161 patients held it for 2 weeks after a seasonal quadrivalent influenza vaccine. Disease activity (DAS28 change, DAS28 flare rate and flare-free survival) was compared between the patients who continued MTX and those held it. A RA flare was defined as an increase in DAS28 of &gt;1.2 or &gt;0.6 if the baseline DAS28 was ≥3.2. <h3>Results</h3> In the 4-week MTX-hold group, the mean DAS28 increased at the 4 weeks after MTX discontinuation by 0.38 ± 0.94 and then improved back to baseline after reintroduction of MTX, whereas the mean DAS28 in the MTX-continue group remained stable over time (Figure 1A). The overall flare-free survival during 20 weeks did not differ between the groups (log rank p=0.142) (Figure 1B). However, numerically more patients in the MTX-hold group experienced a flare than those in the MTX-continue group during the 4-weeks MTX discontinuation (20.5% vs. 7.4%, p=0.058). After resuming MTX, the flare rate did not differ between the groups up to 20 weeks of observations (Figure 1C). A temporary MTX discontinuation for 2 weeks was not associated with any clinically meaningful change in disease activity. <h3>Conclusion</h3> A short-term MTX discontinuation for 2 weeks is safe without any change in disease activity. A 4-week MTX discontinuation is associated with transient increase in disease activity without affecting long-term outcomes. <h3>References</h3> [1] Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017 May 03. [2] Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun; 77(6):898-904. [3] Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016 Jan; 75(1):45-51. <h3>Disclosure of Interests</h3> None declared